Inspiration Biopharmaceuticals uses novel patent protected, recombinant protein manufacturing technologies which are demonstrated to significantly increase cell-line productivity.  This in turn decreases manufacturing capacity requirements, and significantly lowers the overall production cost for Factor products compared with existing manufacturing processes.  Inspiration believes that its technologies will allow introduction of patient friendly, cost-effective products which will provide equal or enhanced potency compared to those currently available.

With the development of advanced delivery systems Inspiration intends to use its proprietary technology to provide  products that offer:

• A cost advantage over current intravenous products.
• Competitively priced non-invasive products suitable for prophylactic therapy.

Inspiration plans to develop its Factor product portfolio in both the intravenous and non-invasive dosage forms to include multiple products for hemophilia and coagulation disorders.

• Factor IX (Hemophilia B)
• Factor VIII (Hemophilia A)
• Factor VIIa (Hemophilia A&B)